Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts

By Balandin Taras   Edelweiss Evelina   Andronova Natalia   Treshalina Elena   Sapozhnikov Alexander   Deyev Sergey  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 22-32

Springer Publishing Company

Access to resources Recommend Favorite

Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer

By Laginha Kimberley   Moase Elaine   Yu Ning   Huang Anthony   Allen T. M.  

Journal of Drug Targeting, Vol. 16, Iss. 7-8, 2008-08 ,pp. : 605-610

Informa Healthcare

Access to resources Recommend Favorite

DIMming Ovarian Cancer Growth

By  

Current Drug Targets, Vol. 13, Iss. 14, 2012-12 ,pp. : 1869-1875

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer

By Hare Jennifer I.   Moase Elaine H.   Allen Theresa M.  

Journal of Drug Targeting, Vol. 21, Iss. 1, 2013-01 ,pp. : 87-96

Informa Healthcare

Access to resources Recommend Favorite

P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer

By  

Current Medicinal Chemistry, Vol. 21, Iss. 4, 2014-02 ,pp. : 501-510

Bentham Science Publishers

Access to resources Recommend Favorite